• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

突触拓扑结构和下调事件决定了抗 CD19 T 细胞重定向策略的功能结果。

Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies.

机构信息

Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital, Universitario 12 de Octubre, Madrid, Spain.

Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain.

出版信息

Oncoimmunology. 2022 Mar 23;11(1):2054106. doi: 10.1080/2162402X.2022.2054106. eCollection 2022.

DOI:10.1080/2162402X.2022.2054106
PMID:35355682
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8959521/
Abstract

Cancer immunotherapy strategies based on the endogenous secretion of T cell-redirecting bispecific antibodies by engineered T lymphocytes (STAb-T) are emerging as alternative or complementary approaches to those based on chimeric antigen receptors (CAR-T). The antitumor efficacy of bispecific anti-CD19 × anti-CD3 (CD19×CD3) T cell engager (BiTE)-secreting STAb-T cells has been demonstrated in several mouse models of B-cell acute leukemia. Here, we have investigated the spatial topology and downstream signaling of the artificial immunological synapses (IS) that are formed by CAR-T or STAb-T cells. Upon interaction with CD19-positive target cells, STAb-T cells form IS with structure and signal transduction, which more closely resemble those of physiological cognate IS, compared to IS formed by CAR-T cells expressing a second-generation CAR bearing the same CD19-single-chain variable fragment. Importantly, while CD3 is maintained at detectable levels on the surface of STAb-T cells, indicating sustained activation mediated by the secreted BiTE, the anti-CD19 CAR was rapidly downmodulated, which correlated with a more transient downstream signaling. Furthermore, CAR-T cells, but not STAb-T cells, provoke an acute loss of CD19 in target cells. Such differences might represent advantages of the STAb-T strategy over the CAR-T approach and should be carefully considered in order to develop more effective and safer treatments for hematological malignancies.

摘要

基于工程化 T 淋巴细胞(STAb-T)内源性分泌 T 细胞重定向双特异性抗体的癌症免疫治疗策略,正在成为基于嵌合抗原受体(CAR-T)的替代或互补方法。几种 B 细胞急性白血病的小鼠模型已经证明了分泌双特异性抗 CD19×抗 CD3(CD19×CD3)T 细胞衔接器(BiTE)的双特异性抗 CD19×抗 CD3(CD19×CD3)T 细胞衔接器(BiTE)-分泌 STAb-T 细胞的抗肿瘤疗效。在这里,我们研究了由 CAR-T 或 STAb-T 细胞形成的人工免疫突触(IS)的空间拓扑结构和下游信号转导。在与 CD19 阳性靶细胞相互作用后,STAb-T 细胞形成具有结构和信号转导的 IS,与 CAR-T 细胞形成的 IS 相比,更类似于生理同源 IS,CAR-T 细胞表达的第二代 CAR 带有相同的 CD19-单链可变片段。重要的是,虽然 STAb-T 细胞表面可检测到 CD3 的水平,表明通过分泌的 BiTE 介导持续激活,但抗 CD19 CAR 迅速下调,这与更短暂的下游信号转导相关。此外,CAR-T 细胞而不是 STAb-T 细胞会引起靶细胞中 CD19 的急性丢失。这些差异可能代表了 STAb-T 策略相对于 CAR-T 方法的优势,在开发治疗血液恶性肿瘤的更有效和更安全的治疗方法时应仔细考虑。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff64/8959521/349e2dd87d0b/KONI_A_2054106_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff64/8959521/355aefe56aa0/KONI_A_2054106_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff64/8959521/3f256fb76973/KONI_A_2054106_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff64/8959521/349e2dd87d0b/KONI_A_2054106_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff64/8959521/355aefe56aa0/KONI_A_2054106_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff64/8959521/3f256fb76973/KONI_A_2054106_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff64/8959521/349e2dd87d0b/KONI_A_2054106_F0003_OC.jpg

相似文献

1
Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies.突触拓扑结构和下调事件决定了抗 CD19 T 细胞重定向策略的功能结果。
Oncoimmunology. 2022 Mar 23;11(1):2054106. doi: 10.1080/2162402X.2022.2054106. eCollection 2022.
2
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.克服 CAR 介导的 CD19 下调和抗 CD19 T 细胞结合物分泌 T 淋巴细胞导致的白血病复发
Cancer Immunol Res. 2022 Apr 1;10(4):498-511. doi: 10.1158/2326-6066.CIR-21-0853.
3
Engineering Immune Cells for Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies.工程化免疫细胞以分泌肿瘤特异性 T 细胞重定向双特异性抗体。
Front Immunol. 2020 Aug 13;11:1792. doi: 10.3389/fimmu.2020.01792. eCollection 2020.
4
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.一种四价双特异性串联抗体(CD19/CD3)AFM11能够有效募集T细胞,从而有力地裂解CD19(+)肿瘤细胞。
MAbs. 2015;7(3):584-604. doi: 10.1080/19420862.2015.1029216.
5
Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models.比较第二代和第三代慢病毒载体转导的 CAR-CD19 T 细胞在体外和体内模型中用于治疗急性淋巴细胞白血病的疗效。
PLoS One. 2023 Feb 13;18(2):e0281735. doi: 10.1371/journal.pone.0281735. eCollection 2023.
6
[CD19 antigen loss after treatment of Bispecific T-cell Engager and effective response to salvage bispecific CAR-T therapy in B cell acute lymphoblastic leukemia: a case report and literature review].[双特异性T细胞衔接器治疗后CD19抗原丢失及对挽救性双特异性嵌合抗原受体T细胞疗法在B细胞急性淋巴细胞白血病中的有效反应:一例报告及文献综述]
Zhonghua Xue Ye Xue Za Zhi. 2020 Apr 14;41(4):282-286. doi: 10.3760/cma.j.issn.0253-2727.2020.04.004.
7
CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.CD20-CD19 双特异性 CAR T 细胞治疗 B 细胞恶性肿瘤。
Hum Gene Ther. 2017 Dec;28(12):1147-1157. doi: 10.1089/hum.2017.126.
8
Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells.构建并功能鉴定表达嵌合抗原受体(huCAR)的全人源抗 CD19 重定向的原代人 T 细胞。
J Cell Physiol. 2019 Jun;234(6):9207-9215. doi: 10.1002/jcp.27599. Epub 2018 Oct 26.
9
Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy.新型全人源抗 CD19 嵌合抗原受体 T 细胞疗法的开发及功能特征研究。
J Cell Physiol. 2021 Aug;236(8):5832-5847. doi: 10.1002/jcp.30267. Epub 2021 Jan 11.
10
Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report.在接受 CAR 转导的白细胞分离产物中鉴定双阳性 CD19+/CD3+ T 细胞:病例报告。
J Immunother Cancer. 2020 Sep;8(2). doi: 10.1136/jitc-2020-001073.

引用本文的文献

1
CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression.分泌CD19 T细胞衔接子的CD22嵌合抗原受体T细胞用于改善对B细胞急性淋巴细胞白血病进展的控制。
J Immunother Cancer. 2025 Apr 30;13(4):e009048. doi: 10.1136/jitc-2024-009048.
2
Rigid crosslinking of the CD3 complex leads to superior T cell stimulation.CD3复合物的刚性交联导致卓越的T细胞刺激。
Front Immunol. 2024 Aug 30;15:1434463. doi: 10.3389/fimmu.2024.1434463. eCollection 2024.
3
A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells.

本文引用的文献

1
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.克服 CAR 介导的 CD19 下调和抗 CD19 T 细胞结合物分泌 T 淋巴细胞导致的白血病复发
Cancer Immunol Res. 2022 Apr 1;10(4):498-511. doi: 10.1158/2326-6066.CIR-21-0853.
2
Increasing LFA-1 Expression Enhances Immune Synapse Architecture and T Cell Receptor Signaling in Jurkat E6.1 Cells.增加淋巴细胞功能相关抗原-1(LFA-1)的表达可增强Jurkat E6.1细胞中的免疫突触结构和T细胞受体信号传导。
Front Cell Dev Biol. 2021 Jul 23;9:673446. doi: 10.3389/fcell.2021.673446. eCollection 2021.
3
FDA approves first BCMA-targeted CAR-T cell therapy.
采用双靶点策略,用抗 IL10R CAR-T 细胞工程改造,使其释放抗 CD33 双特异性抗体,增强对急性髓细胞白血病细胞的杀伤作用。
Cell Oncol (Dordr). 2024 Oct;47(5):1879-1895. doi: 10.1007/s13402-024-00971-5. Epub 2024 Jul 15.
4
Newer generations of multi-target CAR and STAb-T immunotherapeutics: NEXT CART Consortium as a cooperative effort to overcome current limitations.新一代多靶点 CAR 和 STAb-T 免疫疗法:NEXT CART 联盟作为一种合作努力,以克服当前的局限性。
Front Immunol. 2024 May 8;15:1386856. doi: 10.3389/fimmu.2024.1386856. eCollection 2024.
5
Choosing T-cell sources determines CAR-T cell activity in neuroblastoma.选择 T 细胞来源决定了 CAR-T 细胞在神经母细胞瘤中的活性。
Front Immunol. 2024 Mar 27;15:1375833. doi: 10.3389/fimmu.2024.1375833. eCollection 2024.
6
Superantigen-fused T cell engagers for tumor antigen-mediated robust T cell activation and tumor cell killing.用于肿瘤抗原介导的强大T细胞活化和肿瘤细胞杀伤的超抗原融合T细胞衔接器。
Mol Ther. 2024 Feb 7;32(2):490-502. doi: 10.1016/j.ymthe.2023.12.011. Epub 2023 Dec 14.
7
Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy.双特异性抗体形式与癌症免疫治疗中T细胞重定向策略的免疫突触组织
Pharmaceutics. 2022 Dec 30;15(1):132. doi: 10.3390/pharmaceutics15010132.
8
Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers.用分泌抗 CD1a T 细胞结合物的 T 淋巴细胞高效治疗皮质 T 细胞急性淋巴细胞白血病。
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005333.
9
Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs).从 TCR 信号和免疫突触组装中学习,以构建新型嵌合抗原受体 (CAR)。
Int J Mol Sci. 2022 Nov 17;23(22):14255. doi: 10.3390/ijms232214255.
美国食品药品监督管理局批准首款靶向B细胞成熟抗原的嵌合抗原受体T细胞疗法。
Nat Rev Drug Discov. 2021 May;20(5):332. doi: 10.1038/d41573-021-00063-1.
4
CAR T cells better than BiTEs.嵌合抗原受体T细胞比双特异性T细胞衔接器更好。
Blood Adv. 2021 Jan 26;5(2):602-606. doi: 10.1182/bloodadvances.2020003554.
5
The role of trogocytosis in immune surveillance of Hodgkin lymphoma.细胞吞噬作用在霍奇金淋巴瘤免疫监视中的作用。
Oncoimmunology. 2020 Jun 17;9(1):1781334. doi: 10.1080/2162402X.2020.1781334.
6
Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy.旨在防止泛素化和下调的嵌合抗原受体显示出持久的抗肿瘤疗效。
Immunity. 2020 Aug 18;53(2):456-470.e6. doi: 10.1016/j.immuni.2020.07.011. Epub 2020 Aug 5.
7
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis.Amivantamab(JNJ-61186372),一种 Fc 增强的 EGFR/cMet 双特异性抗体,通过单核细胞/巨噬细胞 trogocytosis 诱导受体下调和抗肿瘤活性。
Mol Cancer Ther. 2020 Oct;19(10):2044-2056. doi: 10.1158/1535-7163.MCT-20-0071. Epub 2020 Aug 3.
8
Variant signaling topology at the cancer cell-T-cell interface induced by a two-component T-cell engager.由双组分T细胞衔接器诱导的癌细胞与T细胞界面处的变异信号拓扑结构。
Cell Mol Immunol. 2021 Jun;18(6):1568-1570. doi: 10.1038/s41423-020-0507-7. Epub 2020 Jul 24.
9
Rewired signaling network in T cells expressing the chimeric antigen receptor (CAR).表达嵌合抗原受体 (CAR) 的 T 细胞中的重排信号网络。
EMBO J. 2020 Aug 17;39(16):e104730. doi: 10.15252/embj.2020104730. Epub 2020 Jul 9.
10
Understanding the Spatial Topology of Artificial Immunological Synapses Assembled in T Cell-Redirecting Strategies: A Major Issue in Cancer Immunotherapy.理解在T细胞重定向策略中组装的人工免疫突触的空间拓扑结构:癌症免疫治疗中的一个主要问题。
Front Cell Dev Biol. 2020 Jan 10;7:370. doi: 10.3389/fcell.2019.00370. eCollection 2019.